220 related articles for article (PubMed ID: 29848095)
1. Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
Martí E; Segado A; Pastor-Galán I; Amat P; Remigia MJ; Solano C; Navarro B
Future Cardiol; 2018 May; 14(3s):3-8. PubMed ID: 29848095
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
[TBL] [Abstract][Full Text] [Related]
5. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
Pimentel Quezada Y; Bonilla Palomas JL; Gámez López AL; Moreno Conde M; López Ibáñez MC; Gallego de la Sacristana López-Serrano Á
Future Cardiol; 2018 May; 14(3s):47-53. PubMed ID: 29848089
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.
Gavín Sebastián O; Izuzquiza Fernández M; Martínez Fernández R; Palomera Bernal L
Future Cardiol; 2018 May; 14(3s):25-30. PubMed ID: 29848092
[TBL] [Abstract][Full Text] [Related]
7. Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice.
Pérez Cabeza AI; González Correa JA; Chinchurreta Capote PA; Bravo Marqués R; Ruiz Mateas F; Rosas Cervantes G; Mesa Prado F; López Tejero S; Valle Alberca A
Future Cardiol; 2018 May; 14(3s):9-16. PubMed ID: 29848094
[TBL] [Abstract][Full Text] [Related]
8. CHA
Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
[No Abstract] [Full Text] [Related]
10. Rivaroxaban: from ROCKET-AF trial to routine practice in Spain.
Escobar Cervantes C
Future Cardiol; 2018 May; 14(3s):1-2. PubMed ID: 29848088
[No Abstract] [Full Text] [Related]
11. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
[TBL] [Abstract][Full Text] [Related]
12. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.
Barón-Esquivias G; Marín F; Sanmartín Fernandez M
Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
[TBL] [Abstract][Full Text] [Related]
16. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
Nakagawara J; Ikeda T; Ogawa S; Kitazono T; Minematsu K; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
[TBL] [Abstract][Full Text] [Related]
18. [Rivaroxaban at Non-Valvular Atrial Fibrillation: a Prospective Study and Clinical Practice].
Fonyakin AV
Kardiologiia; 2016 Aug; 56(8):87-92. PubMed ID: 28290887
[TBL] [Abstract][Full Text] [Related]
19. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
Engelberger RP; Noll G; Schmidt D; Alatri A; Frei B; Kaiser WE; Kucher N
Eur J Intern Med; 2015 Sep; 26(7):508-14. PubMed ID: 25935131
[TBL] [Abstract][Full Text] [Related]
20. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
